Diabetes drug shows promise in rectal cancer fight

NCT ID NCT02437656

First seen Mar 18, 2026 · Last updated May 09, 2026 · Updated 10 times

Summary

This study tested whether adding metformin, a common diabetes drug, to standard chemo-radiation before surgery could improve outcomes for people with locally advanced rectal cancer. 60 participants received the combination treatment. The main goal was to see if the cancer completely disappeared in the surgical sample. The study also tracked side effects and whether the treatment helped avoid a permanent colostomy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Centre Galilée - Hôpital Privé La Louvière

    Lille, 59045, France

  • Centre Gray

    Maubeuge, 59600, France

  • Centre Hospitalier

    Lens, 62300, France

  • Centre Joliot-Curie

    Saint-Martin-Boulogne, 62200, France

  • Centre Léonard de Vinci - SARL du pont Saint Vaast

    Douai, 59500, France

  • Centre Marie Curie

    Arras, 62000, France

  • Centre Oscar Lambret

    Lille, 59020, France

  • Centre Pierre Curie

    Beuvry, 62880, France

  • Clinique des Dentellières

    Valenciennes, 59300, France

  • Clinique du Bois - Centre Bourgogne

    Lille, 59000, France

  • Institut André Dutreix

    Dunkirk, 59240, France

Conditions

Explore the condition pages connected to this study.